Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA approves Abraxane for pancreatic cancer

FDA approved an sNDA from Celgene Corp. (NASDAQ:CELG) to expand the label of Abraxane nab-paclitaxel

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE